Menu

A+ A A-

Полный текст статьи

Сергиевич А.В.
Клинико-лабораторные особенности пациентов с псориазом
УО «Витебский государственный ордена Дружбы народов медицинский университет», Республика Беларусь

Резюме.
Псориаз – распространенный, наследственный, Т–клеточный, хронический дерматоз с доброкачественной гиперпролиферацией эпителиоцитов, нарушением их дифференциации и кератинизации, а также патологией органов и систем. В исследование включены 56 человек с псориазом без поражения суставов. Контрольную группу составили 26 здоровых людей. У лиц с псориазом без поражения суставов сывороточный уровень аргиназы I статистически значимо выше, чем в контрольной группе; выявлена статистически значимая умеренная положительная корреляция ФНО-т, ИЛ-1, и ИЛ-6 между собой; определены проатерогенные изменения показателей липидного профиля (повышения сывороточных уровней ОХС, ХС ЛПНП, ТГ, ХС ЛПОНП и снижение сывороточного уровня ХС ЛПВП). Для группы с псориазом выявлена умеренная положительная корреляция аргиназы I с индексом PASI и возрастом; ОХС, ТГ, ХС ЛПОНП с возрастом людей.
Ключевые слова: псориаз, аргиназа I, интерлейкины, липиды.

Литература

1. A prospective case-controlled cohort study of endothelial function in patients with moderate to severe psoriasis / C. L. Martyn-Simmons [et al.] // British Journal of Dermatology. – 2011 Jan. – Vol. 164, N 1. – P. 26–32.
2. Ellis, C. N. Effects of alefacept on health-related quality of life in patients with psoriasis results from a randomized, placebo-controlled phase II trial / C. N. Ellis, M. M. Mordin, E. Y. Adler // American Journal of Clinical Dermatology. – 2003. – Vol. 4, N 2. – P. 131–139.
3. Кожа и сердце. Прямая связь [Электронный ресурс] // MedLinks.ru : [сайт]. – 2006. – Режим доступа: http://www.medlinks.ru/article.php?sid=27740. – Дата доступа: 03.04.2014.
4. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity // L. Lundberg [et al.] // Acta Dermato-Venereologica. – 2000 Nov-Dec. – Vol. 80, N 6. – P. 430–434.
5. Lipid disturbances in psoriasis: an update [Electronic resource] / A. Pietrzak [et al.] // Mediators of Inflammation. – 2010. – Mode of access: http://www.hindawi.com/journals/mi/2010/535612/. – Date of access: 01.04.2014.
6. Псориаз [Электронный ресурс] // Гродненский областной кожно-венерологический диспансер : [сайт]. – Режим доступа: http://gokvd.grodno.by/dzermatologio.php?page=psoriaz. – Дата доступа: 29.03.2014.
7. Clinical, power Doppler sonography and histological assessment of the psoriatic plaque: short-term monitoring in patients treated with etanercept / M. Gutierrez [et al.] // British Journal of Dermatology. – 2011 Jan. – Vol. 164, N 1. – P. 33–37.
8. Immunologic changes in TNF-alpha, sE-selectin, sP-selectin, sICAM-1, and IL-8 in pediatric patients treated for psoriasis with the Goeckerman regimen / L. Borska [et al.] // Pediatric Dermatology. – 2007 Nov-Dec. – Vol. 24, N 6. – P. 607–612.
9. Anti-inflammatory and hypolipidemic effects of the modified fatty acid tetradecylthioacetic acid in psoriasis – a pilot study / T. Morken [et al.] // Scandinavian Journal of Clinical & Laboratory Investigation. – 2011 Jul. – Vol. 71, N 4. – Р. 269–273.
10. Increased expression of the orphan nuclear receptor NURR1 in psoriasis and modulation following TNF-alpha inhibition / M. O’Kane [et al.] // Journal of Investigative Dermatology. – 2008 Feb. – Vol. 128, N 2. – P. 300–310.
11. Psoriasis and diabetes: a population-based cross-sectional study / A. D. Cohen [et al.] // Journal of the European Academy of Dermatology and Venereology. – 2008 May. – Vol. 22, N 5. – Р. 585–589.
12. Psoriatic disease and tuberculosis nowadays [Electronic resource] / N. Balato [et al.] // Clinical and Developmental Immunology. – 2012. – Mode of access: http://www.readcube.com/articles/10.1155/2012/747204. – Date of access: 01.04.2014.
13. Псориаз связан с повышенным риском инфаркта миокарда [Электронный ресурс] // MedLinks.ru : [сайт]. – 2006. – Режим доступа: http://www.medlinks.ru/article.php?sid=27361. – Дата доступа: 03.04.2014.
14. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled phase III study [Electronic resource] / D. A. Revicki [et al.] // Health and Quality of Life Outcomes. – 2008. – Vol. 75, N 6. – Mode of access: http://www.hqlo.com/content/6/1/75. – Date of access: 27.03.2014.
15. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial / A. B. Kimball [et al.] // American Journal of Clinical Dermatology. – 2011 Feb. – Vol. 12, N 1. – P. 51–62.
16. MacDonald, A. Psoriasis: advances in pathophysiology and management / A. MacDonald, A. D. Burden // Postgraduate Medical Journal. – 2007 Nov. – Vol. 83, N 985. – P. 690–697.
17. Infliximab in psoriasis and psoriatic arthritis / M. Papoutsaki [et al.] // Biodrugs: Clinical Immunotherapeutics, Biopharmaceuticals And Gene Therapy. – 2013 Jan. – Vol. 27, Suppl. 1. – P. 13–23.
18. Gottlieb, A. B. Treating psoriatic arthritis: how effective are TNF antagonists? / A. B. Gottlieb, C. E. Antoni // Arthritis Research & Therapy. – 2004. – Vol. 6, Suppl. 2. – P. S31–S35.
19. Kivelevitch, D. Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis / D. Kivelevitch, B. Mansouri, A. Menter // Biologics: Targets & Therapy. – 2014 Apr. – Vol. 8. – P. 169–182.
20. Review article: anti TNF-a induced psoriasis in patients with inflammatory bowel disease / G. Fiorino [et al.] // Alimentary Pharmacology & Therapeutics. – 2009 May. – Vol. 29, N 9. – P. 921–927.
21. Spadaro, A. A novel biological target for the treatment of psoriatic arthritis / A. Spadaro, M. Montepaone, E. Lubrano // Immunotherapy. – 2014 May. – Vol. 6, N 5. – P. 515–518.
22. Expression of interleukin (IL)-1 family members upon stimulation with IL-17 differs in keratinocytes derived from patients with psoriasis and healthy donors / P. Muhr [et al.] // British Journal of Dermatology. – 2011 Jul. – Vol. 165, N 1. – P. 189–193.
23. Alsufyani, M. A. Psoriasis and the metabolic syndrome / M. A. Alsufyani, A. K. Golant, M. Lebwohl // Dermatologic Therapy. – 2010 Mar-Apr. – Vol. 23, N 2. – Р. 137–143.
24. Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: A two-year prospective observational study [Electronic resource] / R. Ramonda [et al.] // Joint, Bone, Spine. – 2014. – Mode of access: http://www.em-consulte.com/en/article/884927. – Date of access: 10.04.2014.
25. Characterization and profiling of immunomodulatory genes in resident mesenchymal stem cells reflect the Th1-Th17/Th2 imbalance of psoriasis [Electronic resource] / A. Campanati [et al.] // Archives Of Dermatological Research. – 2014. – Mode of access: http://mdlinx.pdr.net/dermatology/news-article.cfm/5515047/th1-th17-th2-mesenchymal-stem-cells. – Date of access: 07.09.2014.
26. IL-6 and IL-10 promoteir gene polymorphiisms in psoriasis vulgaris / W. Baran [et al.] // Acta Dermato-Venereologica. – 2008. – Vol. 88, N 2. – P. 113–116.
27. Tobin, A. M. TNFa inhibitors in the treatment of psoriasis and psoriatic arthritis / A. M. Tobin, B. Kirby // BioDrugs. – 2005. – Vol. 19, N 1. – P. 47–57.
28. Side effects of TNF-S blockers in patients with psoriatic arthritis: evidences from literature studies / R. Peluso [et al.] // Clinical Rheumatology. – 2013 Jun. – Vol. 32, N 6. – P. 743–753.
29. Blockade of IL-36 Receptor Signaling Does Not Prevent from TNF-Induced Arthritis [Electronic resource] / A. Derer [et al.] // Plos One. – 2014. – Vol. 9, N 8. – Mode of access: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0101954. – Date of access: 07.09.2014.
30. The novel cytokine interleukin-36T is expressed in psoriatic and rheumatoid arthritis synovium / S. Frey [et al.] // Annals Of The Rheumatic Diseases. – 2013 Sep. – Vol. 72, N 9. – P. 1569–1574.
31. Genetic susceptibility of NLRP1 in psoriasis / A. K. Ekman [et al.] // The British Journal Of Dermatology. – 2014 Dec. – Vol 171, N 6. – P. 1517–1520.
32. IL-19 is a Component of the Pathogenetic IL-23/IL-17 Cascade in Psoriasis [Electronic resource] / E. Witte [et al.] // The Journal Of Investigative Dermatology. – 2014 Nov. – Vol. 134, N 11. – Mode of access: http://www.researchgate.net/publication/264091380_IL-19_is_a_Component_of_the_Pathogenetic_IL-23IL-17_Cascade_in_Psoriasis. – Date of access: 07.09.2014.
33. Interleukin 20 protein locates to distinct mononuclear cells in psoriatic skin / R. Bech [et al.] // Experimental Dermatology. – 2014 May. – Vol. 23, N 5. – P. 349–352.
34. Cytokine gene polymorphisms in Chinese patients with psoriasis / Y. T. Chang [et al.] // British Journal of Dermatology. – 2007 May. – Vol. 156, N 5. – P. 899–905.
35. Namazi, M. R. Possible molecular mechanisms to account for the involvement of tryptase in the pathogenesis of psoriasis / M. R. Namazi // Autoimmunity. – 2005 Sep. – Vol. 38, N 6. – P. 449–452.
36. Arginase activity mediates retinal inflammation in endotoxin-induced uveitis / W. Zhang [et al.] // The American Journal of Pathology. – 2009 Aug. – Vol. 175, N 2. – P. 891–902.
37. Arginase and vascular aging / L. Santhanam [et al.] // Journal of Applied Physiology. – 2008 Nov. – Vol. 105, N 5. – P. 1632–1642.
38. Durante, W. Arginase: a critical regulator of nitric oxide synthesis and vascular function / W. Durante, F. K. Johnson, R. A. Johnson // Clinical and Experimental Pharmacology and Physiology. – 2007 Sep. – Vol 34, N 9. – P. 906–911.
39. Arginase as a target for treatment of myocardial ischemia-reperfusion injury / Y. Tratsiakovich [et al.] // European Journal Of Pharmacology. – 2013. – Vol. 720, N 1/3. – P. 121–123.
40. Durante, W. Role of arginase in vessel wall remodeling [Electronic resource] / W. Durante // Frontiers In Immunology. – 2013. – Vol. 4. – Mode of access: http://journal.frontiersin.org/Journal/10.3389/fimmu.2013.00111/full. – Date of access: 05.04.2014.
41. Arginase is overactive in psoriatic skin / S. Abeyakirthi [et al.] // British Journal of Dermatology. – 2010 Jul. – Vol. 163, N 1. – Р. 193–196.
42. Inhibition of L-arginine metabolizing enzymes by l-arginine-derived advanced glycation end products / Y. L. Lai [et al.] // Journal of Clinical Biochemistry and Nutrition. – 2010 Mar. – Vol. 46, N 2. – P. 177–185.
43. Morris, S. M. Recent advances in arginine metabolism: roles and regulation of the arginases / S. M. Morris // British Journal of Pharmacology. – 2009 Jul. – Vol. 157, N 6. – P. 922–930.
44. Endothelial arginase II: a novel target for the treatment of atherosclerosis / S. Ryoo [et al.] // Circulation Research. – 2008 Apr. – Vol. 102, N 8. – P. 923–932.
45. Subclinical atherosclerosis in patients with chronic psoriasis: a potential association / S. El-Mongy [et al.] // Journal of the European Academy of Dermatology and Venereology. – 2010 Jun. – Vol. 24, N 6. – P. 661–666.
46. Dyslipidemia and oxidative stress in patients of psoriasis / M. Gupta [et al.] // Biomedical Research. – 2011. – Vol. 22, N 2. – Р. 221–224.
47. Hypercholesterolemia and risk of incident psoriasis and psoriatic arthritis in US women / S. Wu [et al.] // Arthritis & Rheumatology. – 2014 Feb. – Vol. 66, N 2. – P. 304–310.
48. Elevated triglyceride and cholesterol levels after intravenous antitumour necrosis factor-a therapy in a patient with psoriatic arthritis and psoriasis vulgaris / C. Antoniou [et al.] // British Journal of Dermatology. – 2007 May. – Vol. 156, N 5. – Р. 1090–1091.
49. Gottlieb, A. B. Psoriasis comorbidities / A. B. Gottlieb, C. Chao, F. Dann // Journal of Dermatological Treatment. – 2008. – Vol. 19, N 1. – Р. 5–21.
50. Prevalence of the metabolic syndrome in children with psoriatic disease / A. M. Goldminz [et al.] // Pediatric Dermatology. – 2013 Nov-Dec. – Vol. 30, N 6. – P. 700–705.
51. Cardiovascular risk profile in patients with spondyloarthritis / C. Papagoras [et al.] // Joint, Bone, Spine: Revue Du Rhumatisme. – 2014 Jan. – Vol. 81, N 1. – P. 57–63.
52. Increased serum leptin and resistin levels and increased carotid intima-media wall thickness in patients with psoriasis: Is psoriasis associated with atherosclerosis? [Electronic resource] / R. M. Robati [et al.] // Journal Of The American Academy Of Dermatology. – 2014. – Mode of access: http://www.jaad.org/article/S0190-9622(14)01567-9/pdf. – Date of access: 08.09.2014.
53. Дерматовенерология 2010 : клинические рекомендации / под общ. ред. А. А. Кубановой; Российское общество дерматовенерологов. – 4-е изд., перераб. и доп. – М. : ДЭКС-Пресс, 2010. – 428 с.
54. Нормы в медицинской практике : справочное пособие / под ред. А. В. Литвинова. – М. : МЕДпресс, 2012. – 144 с.
55. Липопротеины [Электронный ресурс] // Лаборатории Киева и Украины : [сайт]. – Режим доступа: http://laboratories.com.ua/201106301184/lipoproteiny.html. – Дата доступа: 29.03.2014.
56. Serum levels of TNF-a, IFN-y, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity / O. Arican [et al.] // Mediators of Inflammation. – 2005 Oct. – Vol. 2005, N 5. – P. 273–279.
57. Cytokine profiles during infliximab monotherapy in psoriatic arthritis / A. Mastroianni [et al.] // British Journal of Dermatology. – 2005 Sep. – Vol. 153, N 3. – P. 531–536.
58. Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations / M. Viguier [et al.] // Annals of Internal Medicine. – 2010 Jul. – Vol. 153, N 1. – P. 66–67.

Сведения об авторах:
Сергиевич А.В. – аспирант кафедры госпитальной терапии УО «Витебский государственный ордена Дружбы народов медицинский университет».

Адрес для корреспонденции: Республика Беларусь, 210023, г. Витебск, пр. Фрунзе, 27, УО «Витебский государственный ордена Дружбы народов медицинский университет», кафедра госпитальной терапии. Тел.моб.: +375 (29) 216-30-80, e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Сергиевич Александр Владимирович.

 

Поиск по сайту